ALFA Finder| Revenue growth | 37.1% YoY |
|---|---|
| Margins | EBITDA margin improved from 12.4% (Q1FY26) to 14.6%. |
| Demand visibility | Strong export and domestic demand across Pharma and Chemicals. |
| Management confidence | High |
Growth
Revenue grew 37.1% YoY; EBITDA surged 60.7% YoY with margins improving to 14.6%.
Outlook
Expanding non-Ibuprofen business; recent capacity increases in Ethyl Acetate, Acetic Anhydride, and Pantoprazole to drive growth.
Risks
Exposed to raw material price volatility and regulatory compliance across diverse international markets.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 37.1% (= BEAT)
- Guided 14% EBITDA margin → delivered 14.6% (= BEAT)
- Guided mid-teen top line growth → delivered 37.1% (= BEAT)
Partly delivered
- Guided 25% non-Ibu export share by FY27 → currently increasing (= PARTIAL)
Investor Presentation filed with BSE, NSE: IOLCP. Summary written with AI assistance from the document.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹206.97
- Market cap
- ₹6,075 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 29.9×Sector 43.8×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue INR795 cr (+40% YoY), EBITDA INR115 cr (14.4% margin), PAT INR65 cr (+117%). Management now guides ~25%+ FY27 revenue growth.
- Call
- Guides 25% growth
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals delivered strong Q2 results with significant profitability improvements, driven by non-Ibuprofen API growth and cost efficiencies, despite rising raw material prices.
- Call
- Guides 25% growth
IOL Chemicals and Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue ₹795 Cr (+40.1% YoY), EBITDA ₹114.9 Cr (14.4% margin), PAT ₹65 Cr (+116.8%). H1 revenue ₹1,551 Cr (+38.6%). Pivoting to high-value APIs with ₹495 Cr capex plan.
IOL Chemicals and Pharmaceuticals Results Update
IOL Chemicals reported record quarterly revenue, EBITDA and profit for Q2 FY27 and half-year results. Standalone growth was strong, with margins expanding year-on-year.
IOL Chemicals and Pharmaceuticals Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 117.0% YoY
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹795 Cr (+40.1% YoY) and net profit of ₹65.1 Cr (+117.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +117.0% YoY
IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.